A Study in Male and Female Adolescent Participants With Severe Uncontrolled Asthma Starting Treatment With Dupilumab Injection (Dupixent®)

National, Multicentre, Non-interventional, Prospective and Retrospective Study in Adolescent Patients With Severe Uncontrolled Asthma Starting Treatment With Dupilumab (Dupixent®)

Primary objective:

- Describe the characteristics of enrolled severe asthma patients

Secondary objectives:

• Assess the control of asthma under dupilumab (Dupixent®) treatment until 1 year
• Assess the clinical objectives of the asthma care
• Assess comorbidities associated with Type 2 inflammation
• Assess safety during the year of treatment

52 weeks

Inclusion Criteria:

• Adolescents, for whom initiation of dupilumab (Dupixent®) for the severe uncontrolled asthma indication was decided by the investigator before the inclusion in the study
• Adolescents ≥ 12 and < 18 years of age at the time of the initiation of Dupixent® treatment

Exclusion Criteria:

- Adult participants ≥ 18 years of age

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.